Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $227.12 +1.42%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q1 EPS of ($0.25), $0.11 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.57 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
- Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
- Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
